시장보고서
상품코드
2150666

동결건조 시약 비즈 시장 보고서 : 동향, 예측 및 경쟁 분석(-2035년)

Lyophilized Reagent Bead Market Report: Trends, Forecast and Competitive Analysis to 2035

발행일: | 리서치사: 구분자 Lucintel | 페이지 정보: 영문 150 Pages | 배송안내 : 3일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

가격
PDF, Excel & 1 Year Online Access (Single User License) help
PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 4,850 금액 안내 화살표 ₩ 6,553,000
PDF, Excel & 1 Year Online Access (2-5 User License) help
PDF & Excel 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,700 금액 안내 화살표 ₩ 9,053,000
PDF, Excel & 1 Year Online Access (Corporate License) help
PDF & Excel 보고서를 동일 기업 내 동일 국가의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,850 금액 안내 화살표 ₩ 11,959,000
PDF, Excel & 1 Year Online Access (Global License) help
PDF & Excel 보고서를 동일 기업(완전 자회사 포함)의 전 세계 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 10,000 금액 안내 화살표 ₩ 13,513,000
※ 부가세 별도
한글목차
영문목차

동결건조 시약 비드 시장

전 세계 동결건조 시약 비드 시장의 미래는 진단, 제약·바이오기술, 연구·학술기관 및 식품 및 음료 검사 각 시장의 기회에 힘입어 밝은 전망을 보이고 있습니다. 전 세계 동결건조 시약 비드 시장은 2027년 2억 7,900만 달러에서 2035년까지 약 6억 4,300만 달러에 달할 것으로 예상되며, 2027-2035년까지 연평균 성장률(CAGR)은 11.1%를 기록할 전망입니다. 이 시장의 주요 성장 동인으로는 진단 검사 툴의 보급 확대, 안정적인 시약 제제에 대한 수요 증가, 그리고 실험실 자동화 기술에 대한 관심 고조를 들 수 있습니다.

  • Lucintel사의 예측에 따르면 제품 유형별로는 표준 시약 비드의 보급과 합리적인 가격 덕분에 예측 기간 중 ‘표준’ 카테고리가 가장 높은 성장률을 보일 것으로 전망됩니다.
  • 용도별로는 진단 분야에서 안정된 조제 시약을 사용하려는 수요가 높아지고 있으며, 예측 기간 중 가장 높은 성장이 예상됩니다.
  • 지역별로는 북미가 진단 실험실이 잘 갖춰져 있고 생명공학 분야가 발전하고 있으며, 예측 기간 중 가장 높은 성장이 예상됩니다.

동결건조 시약 비드 시장의 새로운 동향

2025-2027년에 동결건조 시약 비드 시장은 전문적인 기술에서 체외 진단 및 검사를 포함한 대규모 시장으로 전환될 전망입니다. 전문적인 기기 및 장비에서 안정적인 시약으로의 전환에 따라 진단·검사 시설의 물류가 간소화될 것입니다. 또한 동결건조 시약은 진단 업계의 목표에 부합하는 방향으로 발전할 것입니다. Lucintel사는 진단 업계를 혁신할 몇 가지 장기적인 동향을 제시하고 있습니다.

  • 콜드 체인 축소: 2025년, 진단 업계는 더 높은 온도에서 시약의 안정화에 주력하는 한편, WHO는 더 낮은 온도에서 검사의 안정화에 주력할 전망입니다. 그러나 양측 모두 검사 키트가 냉장 온도에서 운송 및 보관되는 시간을 최소화하는 것을 목표로 하고 있습니다. 극한 온도에서도 시약을 안정화시키는 것은 진단 검사의 운송 과정에서 발생하는 폐기물을 줄이는 데에도 기여할 것입니다.
  • 자동화를 통한 호환성: 진단 업계는 실험실내 검사 자동화에 주력할 것입니다. 시약은 신속하게 용해되도록 제조되므로, 검사 기기가 검사를 처리할 수 있는 시간이 연장되고, 기기의 교정 및 유지보수에 소요되는 시간과 비용이 절감됩니다. 자동화된 실험실에서의 검사는 증가하여 표준이 될 것입니다.
  • 다중 분자 검사: 다양한 감염증 및 암을 대상으로 한 다중 분석법의 급속한 확대에 더해, 2025년까지 모의 검체의 도입이 진행됨에 따라 증후군별 검사의 도입이 촉진될 것으로 예상됩니다. 다중 제형화 기법이 간소화됨에 따라 더 많은 증후군별 검사 분석법의 개발이 촉진될 것으로 전망됩니다.
  • 품질 설계(QbD): 부형제의 중요한 특성에 대한 관리를 강화하기 위한 제조 공정의 지속적인 개선을 통해 2027년까지 수탁제조업체가 더 확신을 가지고 비드 로트를 출시할 수 있게 될 것으로 예상됩니다.
  • 지역별 공급업체의 다양화: COVID-19 팬데믹을 계기로 진단약 제조업체들은 효소, 플라스틱, 포장 자재의 조달처를 대체 공급처로 확대했습니다. 또한 팬데믹은 전략적 제휴 및 조달 제휴의 형성을 촉진했습니다. 향후 수년간 조달처의 집중도는 낮아질 전망이지만, 특수 첨가제의 경우 이와 같은 경향은 나타나지 않을 것입니다.

동결건조 시약 비드 및 카트리지의 장점은 향후 5년 동안 분명해질 것입니다. 증후군 진단은 특히 저·중소득 국가에서 더욱 보급될 전망입니다. 제조 및 공급 체계의 개선을 통해 더 많은 지역에서 증후군 진단이 일상화될 것입니다.

동결건조 시약 비드 시장의 최근 동향

동결건조 시약 비드 시장은 급속히 성장하고 있으며, 분석 관련 공정에서 안정화 기술의 활용으로 전환되고 있습니다. 2025-2027년는 주로 분산형 진단 시스템의 도입 확대 및 공급망과 물류의 현지화에 힘입어 견고한 성장세가 예상됩니다. 따라서 비드의 화학적 특성 외에도 성능과 자동 디스펜서 시스템이 경쟁의 핵심 분야가 될 것입니다.

  • POC(Point-Of-Care)(Point-of-Care) 시스템에 대한 관심 증가: 2025년 2월, Quidel Ortho사는 자사의 ‘Savanna’ 분자 진단 시스템의 검사 메뉴를 확충했습니다. 이에 따라 소형 통합 시스템에 대한 수요가 증가하며, 신속 검사용 비드의 활용이 촉진되고 있습니다.
  • 현지 생산으로의 동향: 2025년 3월, Salmon Fisher사는 미국내 진단약 제조를 위해 15억 달러를 투자하겠다고 발표했습니다. 시약의 현지 생산은 비드의 현지 생산을 촉진할 것입니다.
  • 전략적 제휴 동향: 2025년 5월, Bio-Rad사는 3가지 분자 검사법의 개발 및 상용화를 목적으로 지역 진단약 기업과 제휴를 맺었습니다.
  • 분산형 검사: 2025년 6월, FDA는 4가지 표적을 검사하고 환자 측에서 검사가 가능하도록 하는 분자 호흡기 패널을 승인했습니다. 이로 인해 운송 및 보관 조건과 같은 물류상 과제, 숙련된 인력 확보의 어려움, 비용 측면의 영향 등 액체 검사 시행에 제약 요인이 존재하는 지역에서 안정화된 시약에 대한 수요가 촉진될 것으로 예상됩니다.
  • 자동화 및 규모 확대: 2025년 9월, 한 진단용 의약품 수탁제조업체가 연간 2,000만 건의 검사에 대응할 수 있는 검사 키트 충전 장치의 검증 절차를 완료했습니다. 검사 키트 생산 자동화의 지속적인 개선을 통해 동결건조 검사 키트의 대규모 생산이 촉진되어, 대규모 감염병 검사에서 비용, 일관성 및 로트 크기의 개선이 기대됩니다.

시약 비드의 혁신으로 인해 감염병 검사 키트의 제조가 용이해질 것으로 예상됩니다. 주목할 점은 진단 분야의 기존 대기업으로, 이들 기업은 위탁 제조 기관과 제휴하여 진단용 충전 자동화를 추진하고, 지역별 규제 당국의 승인을 획득하게 될 것입니다. 장기적으로는 단가가 지역 간 검사 플랫폼의 표준화에 따라 결정될 것입니다.

목차

제1장 개요

제2장 시장 개요

제3장 시장 동향과 예측 분석

제4장 세계의 동결건조 시약 비즈 시장 : 제품 유형별

제5장 세계의 동결건조 시약 비즈 시장 : 용도별

제6장 지역별 분석

제7장 북미의 동결건조 시약 비즈 시장

제8장 유럽의 동결건조 시약 비즈 시장

제9장 아시아태평양의 동결건조 시약 비즈 시장

제10장 RoW의 동결건조 시약 비즈 시장

제11장 경쟁 분석

제12장 기회와 전략 분석

제13장 밸류체인 전체에서 주요 기업의 기업 개요

제14장 부록

KSA 26.10.22

Lyophilized Reagent Bead Market

The future of the global lyophilized reagent bead market looks promising with opportunities in the diagnostic, pharmaceutical & biotechnology, research & academic laboratory, and food & beverage testing markets. The global lyophilized reagent bead market is expected to reach an estimated $643 million by 2035 from $279 million in 2027 with a CAGR of 11.1% from 2027 to 2035. The major drivers for this market are the increasing adoption of diagnostic testing tools, the rising demand for stable reagent formulations, and the growing focus on lab automation technologies.

  • Lucintel forecasts that, within the product type category, standard is expected to witness the highest growth over the forecast period due to the widespread use and affordability of standard reagent beads.
  • Within the application category, diagnostics is expected to witness the highest growth over the forecast period due to the increasing need for diagnostics to use stable, prepared reagents.
  • In terms of regions, North America is expected to witness the highest growth over the forecast period due to well-developed diagnostic laboratories and a progressive biotechnology sector.

Emerging Trends in Lyophilized Reagent Bead Market

From 2025 to 2027, the lyophilized reagent bead market will move away from specialized technology and toward large-scale markets, including in vitro diagnostics and tests. Shifting to stable reagents and away from specialized instrumentation and equipment will simplify logistics for diagnostic and testing laboratories. Additionally, lucitable reagents would be in line with the goals of the diagnostic industry. Lucintel has listed several long-term trends that transform the diagnostics industry.

  • Cold Chain Reduction: In 2025, the diagnostics industry will focus on stabilizing reagents at higher temperatures, while the WHO will focus on stabilizing tests at lower temperatures. Both, however, seek to minimize the time a test is shipped and stored at refrigerated temperatures. Stabilizing reagents to extreme temperatures will also reduce waste during the transportation of diagnostic tests.
  • Automatic Compatibility: The diagnostics industry will focus on the automation of laboratory testing. Reagents will be manufactured to rapidly dissolve, thus increasing the time a piece of laboratory equipment can process tests and reducing the time and cost associated with calibrating and maintaining a piece of equipment. Automated laboratory testing will increase and become standard.
  • Multiplex Molecular Testing: Rapid expansion of multiplexed assays targeting various infectious diseases and cancers, along with the introduction of mock samples by 2025, is expected to facilitate the adoption of syndromic testing. Simplified methods for multiplex formulation are expected to encourage the development of more syndromic testing assays.
  • Quality By Design: Continuous improvements in manufacturing to increase control over critical attributes of excipients is expected to allow contract manufacturers to release bead lots with greater confidence by 2027.
  • Regional Supplier Diversification: The COVID-19 pandemic stimulated diagnostic manufacturers to source enzymes, plastics, and packaging from alternatives. Further, the pandemic encouraged the formation of strategic collaborations and sourcing alliances. While sourcing will become less concentrated during the next several years, the same will not hold true for specialized excipients.

The advantages of lyophilized reagent beads and cartridges will become evident over the next five years. Syndromic testing will become more pervasive, especially in lower and middle-income countries. Improvements in manufacturing and supply will allow syndromic testing to become routine in more locations.

Recent Developments in the Lyophilized Reagent Bead Market

The lyophilized reagent bead market is rapidly growing and is shifted more toward the use of stabilization technology in assay-related processes. During the years 2025 to 2027, a positive growth trend is expected mainly because of the increase in deployments of distributed diagnostic systems, and the localization of supply chain and logistics. Therefore, performance and automated dispenser systems would be areas of competitive focus, in addition to chemistry of the beads.

  • Increased Emphasis on Point-of-care Systems: In February 2025, Quidel Ortho extended the assay menu of its Savanna molecular system, thereby increasing the demand for compact integrated systems and fosters the use of beads for rapid tests.
  • Trend Toward Localized Production: In March 2025, Thermon Fisher announced a USD 1.5 billion investment toward diagnostics manufacturing in the US. Localized production of reagents would stimulate the local production of beads.
  • Trend Toward Strategic Alliances: In May 2025, Bio-Rad entered into alliances with a regional diagnostics firm to develop and commercialize three molecular assays.
  • Decentralized Testing: In June 2025, the FDA approved a molecular respiratory panel to test four targets and allow patient-side testing. This should stimulate demand for the stabilized reagents where imitating factors for performing liquid tests, like the logistics of transport and refringence, inconvenience of skilled personnel, and cost impact, exist.
  • Automation and Scale-up: In September 2025, a diagnostics contract manufacturer validated a test filling unit for 20 million tests per year. Continuous improvement in test production automation is expected to stimulate large scale production of lyophilized tests, improving cost, consistency and batch size, for large scale, infectious disease, testing.

Innovation in reagent beads is expected to ease the production of infectious disease tests. The focus will be on the established players in the diagnostics field, who will partner with contract manufacturing organizations to automate diagnostics filling, and gain regional regulatory clearances. Long term, the price-per-unit will depend on the standardization of test platforms across regions.

Strategic Growth Opportunities in the Lyophilized Reagent Bead Market

From 2024 to 2026, clinical laboratories will implement more automated and multiplexed tests. During this time, the demand for stable, prepared reagents will increase. Continuity of supply and the 2022 EU In Vitro Diagnostic Regulations (IVDR) will increase the preference for reagents with a longer shelf life. Lyophilized reagents will find a market outside of clinical chemistry.

  • Decentralized Diagnostics: Lyophilized reagent beads will enable compact instrumentation for diagnostic testing and, with further reduction in size, may enable point-of-care testing. The WHO's 2025 report stated that diagnostic testing in primary care is essential to achieve universal health coverage. Stability of reagents at room temperature will allow decentralized diagnostic testing.
  • Molecular Diagnostics: Beads can be used to simplify laboratory assays. With the 2027 expiration date for many devices containing reagents prepared by laboratory personnel, suppliers will have time to convince customers (diagnostic laboratories) to use bead-based molecular tests in their assays.
  • Stability of Reagents for Food and Environmental Testing: Food and water processing companies as well as laboratories require reagents that can tolerate variations in storage and transportation. The European Commission's microbiological criteria framework states that food processing companies should define pathogen control strategies and provide relevant documentation. Lytophilisates reduce errors and increase the speed of pathogen tests.
  • Premium Multiplex Products: The food and pharmaceutical industry can charge higher prices for multiplex kits containing beads with a reagent system and controls. In April 2025, the FDA released a list of 20+ respiratory pathogens that can be tested through multiplex assays. The industry trend is to develop integrated, multiplex assays to reduce the number of samples collected from a patient and to decrease the hands-on time for the laboratory personnel.
  • Distribution and Storage: Suppliers can focus on market regions where a reliable cold chain is lacking. In March 2025, UNICEF stated that many countries do not have a reliable cold chain to distribute vaccines and other temperature sensitive medications. Products in a lyophilized state can be stored at room temperature and decrease the volume of product shipped.

Suppliers can differentiate their products through a combination of multiple technologies to create a stable and formulated reagent system that is integrated into an automated dispenser. Decentralized testing, food and animal testing, and industry 4.0 are just a few of the markets that will show the greatest growth.

Lyophilized Reagent Bead Market Drivers and Challenges

Continuous improvements in technology and automation, as well as increasing healthcare expenditures and changes in regulatory frameworks, offer significant growth opportunities in the lyophilized reagent bead market. Use of ready-to-use lyophilized reagents in in-house, on-site and remote diagnostic testing is likely to gain traction in the near future.

The factors responsible for driving this market include:

  • Increased Customer Awareness: There is growing awareness about the advantages of using lyophilized reagent beads for diagnostic testing. Compared to traditional liquid reagents, lyophilized reagents offer longer stability and require less time and effort for preparation. The World Health Organization's (WHO) efforts to enhance access to essential diagnostic services and reagents worldwide have also created a positive business environment for lyophilized reagents. The WHO's Global Diagnostic Agenda 2016-2030 outlines the organization's commitment to expanding access to essential diagnostics. Many public and private healthcare systems have adopted this agenda and will likely increase their testing capacity in the next three to five years in an effort to improve the efficiency of their laboratories.
  • Advances in Manufacturing and Formulation: Increased understanding of reagent formulation and manufacturing has resulted in more reliable and accurate reagents. Manufacturers are finding ways to improve the stability of enzymes and other biomolecules by encapsulating them in beads that are protected from the environment. Faster dissolving beads are also being developed. Furthermore, some reagents are becoming more stable at higher temperatures. The authors state that, in the coming years, these advances will increase the range of reagents available for biomolecular and other assays.
  • Increased Standards and Regulation: There is a consistent effort to increase the quality and standards in the diagnostic field and this leads to a heightened acceptance of standardized reagents. Lyophilized reagents, when validated to reduce contamination risk and improve consistency, are considered a positive change from the field. The authors state that in 2025, the EU continued enforcing the IVDR. This increased focus on the regulations strengthened the need for quality and post-market surveillance. It is expected that in the next five years, suppliers of diagnostic reagents would need to develop and manufacture products to the same standards to operate in the EU.
  • Sustainability: Laboratories are focused on "decarbonizing" their processes, and Lyophilized reagent beads can help facilitate these efforts by stabilizing reagents and minimizing the need for refrigerated transport and disposal of Spent reagents. In April 2025, several sustainability programs targeted the emissions from laboratory refrigeration and other transport. Over the next 3 to 5 years, in addition to improving energy and resource efficiency of diagnostic services, procurement decisions will also be influenced by the need to minimize the diagnostic system's carbon footprint, for example by public health and diagnostics facilities.
  • Manufacturing: Continuous improvements in process and automation for bead manufacturing have improved consistency and minimized costs. The automation and standardization of reagent beads further reduces labour and handles in assay reagents. In June 2025, bead-based automation in diagnostics further facilitated high throughput and decentralized diagnostic tests. Improved manufacturing processes combined with an emphasis on customization will allow supplier companies to better serve smaller diagnostic facilities and international markets.

The challenges facing this market include:

  • Complex Formulation: Lyophilizing beads to maintain biologic activity and enhance stability, especially for diagnostic applications, requires significant experience and know-how. Proteins, enzymes, antibodies, nucleic acids, and other biologics may not maintain their activity and stability with various excipients and under different conditions of drying and storage. Moreover, different beads may require different formulation and stabilization strategies. In May 2025, many companies in the diagnostics space focused on accelerated stability studies to assess the impact of storage, transportation and use conditions on their diagnostic kit. Over the next 5 years, differentiating formulation strategies will further increase the costs, time and number of suppliers for diagnostic kits.
  • High Costs of Doing Business: The diagnostics space requires significant up-front investment for expansion and conformity with stringent quality and regulatory standards. In August 2025, most diagnostics companies focused on stability and comparability studies to meet regulatory demands. Over the next 5 years, high costs of doing business will increase market consolidation and reliance on Contract Development and Manufacturing Organizations (CDMOs).
  • Risks To The Supply Chain and Storage: Lyophilization enhances stability of biological products; however, there are a number of factors that still affect the final product. Moisture content is one such factor. Other factors include use of specialty excipients, packaging, storage, and transportation. Reliance on sophisticated and expensive equipment and biologics can also affect the supply chain. Healthcare supply chains improved in October 2025 by building inventory and utilizing multiple sources. In the coming years, supply chain partners must improve packaging and monitoring of their products, and adjust their sourcing to meet customer requirements.

The positive trends for diagnostics (automation and sustainability) are driving the use of lyophilized reagents and improving the quality of diagnostic products. Additionally, with improved manufacturing, the physical and logistical burdens of product distribution and transportation may be reduced. However, there may be supply limitations due to formulation complexities and supply chain vulnerabilities. Continuous improvements in manufacturing may allow a competitive edge to be sustained in the diagnostic products market. Improvements in manufacturing, distribution, and product design will allow a company to support the goal of providing safe, reliable, and affordable diagnostics in high- and low-resource environments.

List of Lyophilized Reagent Bead Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies lyophilized reagent bead market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the lyophilized reagent bead market companies profiled in this report include-

  • Sanofi
  • PharmaJet Partner Gennova Biopharmaceuticals
  • Pfizer
  • Mylan NV
  • Merck & Co.
  • GlaxoSmithKline Plc
  • Fresenius Kabi AG
  • Ciron Drugs & Pharmaceuticals Pvt. Ltd.
  • Berkshire Sterile Manufacturing
  • Amneal Pharmaceuticals LLC

Lyophilized Reagent Bead Market by Segment

The study includes a forecast for the global lyophilized reagent bead market by product type, application, and region.

Lyophilized Reagent Bead Market by Product Type [Value ($M) from 2019 to 2035]:

  • Standard
  • Customized
  • Multiplex
  • Pre-Mixed

Lyophilized Reagent Bead Market by Application [Value ($M) from 2019 to 2035]:

  • Diagnostics
  • Pharmaceutical & Biotechnology
  • Research & Academic Laboratories
  • Food & Beverage Testing

Lyophilized Reagent Bead Market by Region [Value ($M) from 2019 to 2035]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Lyophilized Reagent Bead Market

The lyophilized reagent bead market is shifting from convenience in the lab to combination with other diagnostic tests in an integrated system. During 2025 to 2027, manufacturers are focusing on development of products that are in the form of automated, self-contained, and disposable cartridges. Lucintel is of the view that, in the near term, the market would depend on the extent of acceptance gained by the instruments manufactured by different vendors.

  • United States: Funds allocated by the U.S. Government for the manufacture of in-country diagnostic kits and the $200 million grant announced in February 2025 by the National Institutes of Health (NIH) through its Rapid Test Transformation (RADx) program are likely to catalyse the development of bead-based rapid diagnostic tests and facilitates their commercialization in the country.
  • China: During the study period, China concentrated on localizing critical diagnostic reagents. More automated molecular diagnostic systems are expected to foster further integration of automated diagnostic systems in the country. The presence of automated diagnostic systems in various locations offers an opportunity to Chinese manufacturers to produce consumable kits for molecular diagnostics.
  • Germany: Germany's diagnostics industry is continuing its growth, and in January 2025 Siemens Healthineers announced €5.5 billion in quarterly revenue from its diagnostics business. In 2025, further investment was made to enhance the automation and decentralization of diagnostics. The focus of this investment is expected to drive changes in bead-based sample collection and diagnostics in the EU.
  • India: Supported by the Indian government, local production of molecular diagnostic testing is increasing. In April 2025, Molbio Diagnostics announced its Truenat diagnostic systems (which include the reagents) is being used in over 80 countries. In the coming years, it is likely that similar systems and components will be manufactured in India.
  • Japan: Japan is expected to continue its emphasis on high-quality diagnostics. In May 2025, Sysmex (a leading Japanese diagnostics company) reported a 5.6% increase in its diagnostics systems business, and further investment was made to automate its hematology diagnostic systems.

Features of the Global Lyophilized Reagent Bead Market

  • Market Size Estimates: lyophilized reagent bead market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
  • Segmentation Analysis: lyophilized reagent bead market size by product type, application, and region in terms of value ($B).
  • Regional Analysis: lyophilized reagent bead market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different product types, applications, and regions for the lyophilized reagent bead market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the lyophilized reagent bead market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the lyophilized reagent bead market by product type (standard, customized, multiplex, and pre-mixed), application (diagnostics, pharmaceutical & biotechnology, research & academic laboratories, and food & beverage testing), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.1 Macroeconomic Trends and Forecasts
  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global Lyophilized Reagent Bead Market by Product Type

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Product Type
  • 4.3 Standard : Trends and Forecast 2019 to 2035
  • 4.4 Customized : Trends and Forecast 2019 to 2035
  • 4.5 Multiplex : Trends and Forecast 2019 to 2035
  • 4.6 Pre-Mixed : Trends and Forecast 2019 to 2035

5. Global Lyophilized Reagent Bead Market by Application

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Application
  • 5.3 Diagnostics : Trends and Forecast 2019 to 2035
  • 5.4 Pharmaceutical & Biotechnology : Trends and Forecast 2019 to 2035
  • 5.5 Research & Academic Laboratories : Trends and Forecast 2019 to 2035
  • 5.6 Food & Beverage Testing : Trends and Forecast 2019 to 2035

6. Regional Analysis

  • 6.1 Overview
  • 6.2 Global Lyophilized Reagent Bead Market by Region

7. North American Lyophilized Reagent Bead Market

  • 7.1 Overview
  • 7.2 North American Lyophilized Reagent Bead Market by Product Type
  • 7.3 North American Lyophilized Reagent Bead Market by Application
  • 7.4 The United States Lyophilized Reagent Bead Market
  • 7.5 Canadian Lyophilized Reagent Bead Market
  • 7.6 Mexican Lyophilized Reagent Bead Market

8. European Lyophilized Reagent Bead Market

  • 8.1 Overview
  • 8.2 European Lyophilized Reagent Bead Market by Product Type
  • 8.3 European Lyophilized Reagent Bead Market by Application
  • 8.4 German Lyophilized Reagent Bead Market
  • 8.5 French Lyophilized Reagent Bead Market
  • 8.6 Italian Lyophilized Reagent Bead Market
  • 8.7 Spanish Lyophilized Reagent Bead Market
  • 8.8 The United Kingdom Lyophilized Reagent Bead Market

9. APAC Lyophilized Reagent Bead Market

  • 9.1 Overview
  • 9.2 APAC Lyophilized Reagent Bead Market by Product Type
  • 9.3 APAC Lyophilized Reagent Bead Market by Application
  • 9.4 Chinese Lyophilized Reagent Bead Market
  • 9.5 Indian Lyophilized Reagent Bead Market
  • 9.6 Japanese Lyophilized Reagent Bead Market
  • 9.7 South Korean Lyophilized Reagent Bead Market
  • 9.8 Indonesian Lyophilized Reagent Bead Market

10. ROW Lyophilized Reagent Bead Market

  • 10.1 Overview
  • 10.2 ROW Lyophilized Reagent Bead Market by Product Type
  • 10.3 ROW Lyophilized Reagent Bead Market by Application
  • 10.4 Middle Eastern Lyophilized Reagent Bead Market
  • 10.5 South American Lyophilized Reagent Bead Market
  • 10.6 African Lyophilized Reagent Bead Market

11. Competitor Analysis

  • 11.1 Product Portfolio Analysis
  • 11.2 Operational Integration
  • 11.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

  • 12.1 Value Chain Analysis
  • 12.2 Growth Opportunity Analysis
    • 12.2.1 Growth Opportunity by Product Type
    • 12.2.2 Growth Opportunity by Application
  • 12.3 Emerging Trends in the Global Lyophilized Reagent Bead Market
  • 12.4 Strategic Analysis
    • 12.4.1 New Product Development
    • 12.4.2 Certification and Licensing
    • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

  • 13.1 Competitive Analysis Overview
  • 13.2 Sanofi
    • Company Overview
    • Lyophilized Reagent Bead Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.3 PharmaJet Partner Gennova Biopharmaceuticals
    • Company Overview
    • Lyophilized Reagent Bead Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.4 Pfizer
    • Company Overview
    • Lyophilized Reagent Bead Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.5 Mylan NV.
    • Company Overview
    • Lyophilized Reagent Bead Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.6 Merck & Co.
    • Company Overview
    • Lyophilized Reagent Bead Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.7 Glaxosmithkline Plc
    • Company Overview
    • Lyophilized Reagent Bead Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.8 Fresenius Kabi AG
    • Company Overview
    • Lyophilized Reagent Bead Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.9 Ciron Drugs & Pharmaceuticals Pvt. Ltd.
    • Company Overview
    • Lyophilized Reagent Bead Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.10 Berkshire Sterile Manufacturing
    • Company Overview
    • Lyophilized Reagent Bead Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.11 Amneal Pharmaceuticals LLC
    • Company Overview
    • Lyophilized Reagent Bead Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

14. Appendix

  • 14.1 List of Figures
  • 14.2 List of Tables
  • 14.3 Research Methodology
  • 14.4 Disclaimer
  • 14.5 Copyright
  • 14.6 Abbreviations and Technical Units
  • 14.7 About Us
  • 14.8 Contact Us
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
email
문의하기